Geniculate Artery Embolization for Osteoarthritis

Last updated: June 27, 2025
Sponsor: University of Minnesota
Overall Status: Active - Recruiting

Phase

N/A

Condition

Osteoarthritis

Joint Injuries

Treatment

Geniculate Artery Embolization

Clinical Study ID

NCT04456569
RAD-2019-27368
  • Ages 40-70
  • All Genders

Study Summary

The need for exploration of more definitive and cost effective non-arthroplasty treatments of osteoarthritis (OA) has been demonstrated by the orthopedic and health economic research.

Embolotherapy of neovessels associated with OA joints has been shown to be promising in patients with knee OA. There is a need for level one evidence drawn from randomized clinical trials to prove the safety, feasibility and efficacy of knee embolotherapy compared to standard of care.

This randomized pilot study will assign 10 patients with mild-moderate OA to undergo geniculate artery embolization plus standard of care (defined in this study as: physical therapy and oral anti-inflammatory medications, with a maximum of 1 joint injection at the time of enrollment) and 10 patients to receive only medical standard of care (also having had a maximum of 1 joint injection prior to enrollment). The goal of this pilot study is to obtain preliminary estimates of safety and efficacy of embolotherapy to provide sustained symptom control and modify disease progression in patients with mild to moderate knee OA.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Between 40 - 70 years of age.

  • Unilaterally dominant symptomatic OA (bilateral radiographic OA will not exclude).

  • Symptomatically refractory of at least 3 months of medical and/or rehabilitationmeasures (anti-inflammatory drugs, and/or physical therapy, and/or strengthconditioning, and/or intra-articular injections of the affected knee in the last 3months).

  • Kellgren-Lawrence grade 1, 2, or 3 on radiograph of the knee

  • Willing to comply with the protocol requirements and willing to undergo non-contrast MRI during screening and at 12 months.

  • Willing to comply with regular follow up during the 12 month follow-up period.

  • Not a current candidate for partial or total knee arthroplasty.

  • WOMAC Score >=6 in at least 2 categories.

Exclusion

Exclusion Criteria:

  • BMI >35 kg/m2

  • Advanced peripheral arterial disease (resting ABI <= 0.9).

  • Known significant peripheral arterial disease precluding common femoralcatheterization

  • Have smoked tobacco regularly (smoking 1 or more tobacco product(s) per week) withinthe last year

  • Diabetics with hemoglobin A1C of >9%

  • Previous lower extremity embolization

  • Uncontrolled emotional disorders per patient medical history

  • Chronic pain syndrome or currently under a pain contract.

  • Anatomic variants involving the lower extremities which would increase the risk ofnon-target embolization

  • Renal insufficiency based on an estimated GFR<45 ml/min who are not already onhemodialysis.

  • Abnormal INR (>1.5)

  • Platelet count <50x109/L.

  • Currently receiving medications for anticoagulation which cannot safely be held forthe procedure and for 7 days post-procedure.

  • Known severe allergy to iodine which cannot be adequately pre-medicated

  • Pregnant or intend to become pregnant within 6 months of the procedure

  • Contraindication to drugs used for moderate sedation during interventionalprocedures, including Midazolam and Fentanyl

  • Life expectancy <60 months

  • Currently enrolled or who plan to enroll in other investigations that conflict withfollow-up testing or confounds data in this trial

  • Contraindications to medical and physical rehabilitative treatments of OA.

  • Advanced atherosclerosis.

  • Current or previous lower extremity fistula.

  • Rheumatoid arthritis or seronegative arthropathies.

  • WOMAC Pain Scale < 6

  • Steroid injection in the affected joint within 3 months of screening. I- ninvestigator assessment, patient is not a candidate for study participation

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: Geniculate Artery Embolization
Phase:
Study Start date:
February 01, 2022
Estimated Completion Date:
February 01, 2026

Study Description

This is a single center, two-arm, open label, pilot study to assess feasibility and safety and obtain a preliminary estimate of efficacy of geniculate artery embolization in reducing pain compared to a control group undergoing conservative presurgical management. The 20 patients will be randomly divided into two groups of 10 in 1:1 allocation. One group will have embolization of the geniculate artery branches and standard of care while the other will have only the standard care. Following the completion of the 10 participants in each arm, a safety and data review will be undertaken (Visit 4 in the GAE group and Visit 2 of the SOC). The data will be assessed regarding the trends between the groups as they relate to KOOS/WOMAC pain scale, MRI / Xray evaluation of OA, and presence of inflammatory biomarkers.

Connect with a study center

  • University of Minnesota

    Minneapolis, Minnesota 55455
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.